Jeffrey Anderson was appointed our President in March 2019. Prior to that he served as our Senior Vice President of Clinical and Regulatory affairs since December 2013, overseeing all aspects of the clinical evaluation and regulatory approval of the Company’s products as well as the commercial launch in several key markets. Previously, he served as our Vice President of Clinical and Regulatory affairs from 2004 to 2008, and again from February 2011 until his promotion to Senior Vice President. He has over 25 years of experience in the medical device industry, including his positions of Vice President of Clinical & Regulatory Affairs and Vice President of Research & Development for Neomend, a biomedical device company engaged in the development and commercialization of surgical wound healing products, where he served from October 2008 through February 2011. Additionally, Mr. Anderson has held senior positions at Abbott Vascular, Jomed, CRS Clinical Research, and Medtronic. He received his B.S. in Physics from California State University at Fullerton.
Leigh Elkolli was appointed our Chief Financial Officer and Corporate Secretary on January 4, 2019. She brings over 20 years of public accounting and finance experience, including 17 years in the life sciences industry in both publicly traded and privately held Companies. She has served as the Company’s Senior Director of Finance and Corporate Controller since August 2017. Prior to her tenure with the Company, Ms. Elkolli was the Director of Finance at Avidity Biosciences, a privately held biotech company and Director of Finance at ImpediMed, Inc., a publicly traded medical device company. Prior to that, Ms. Elkolli served in a variety of roles, most recently as an audit manager, at Ernst & Young, LLP. Ms. Elkolli received an A.S. in Accounting from Champlain College and a B.B.A. in Accounting from Western Connecticut State University. She is a certified public accountant with the State of California.
Jessica Earley was appointed our Vice President of Operations and Product Development in January 2019. She has been with REVA since 2003 and directed the scaffold development program since 2015 and operations since 2016. In her 18 years of industry experience, she has held engineering, program management and operational management positions in the pharmaceutical and medical device industries. Jessica holds a Chemical Engineering degree from the University of New Hampshire.
Board of Directors
Mr. Larkin was appointed as a director in July 2017. He currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. Prior to Group Outcome, Mr. Larkin was Chairman and CEO at Eunoe Inc., an investigative device for slowing and stopping progression of Alzheimer’s disease. From 2001 to 2007, he served as a part-time Venture Partner at Cutlass Capital, a venture capital firm. Prior to that, he was President and Chief Executive Officer of Nellcor Puritan Bennett, Inc., a respiratory products company. Mr. Larkin also held positions of increasing responsibility at Bentley Laboratories/American Hospital Supply from 1976 to 1983. Mr. Larkin currently serves as board chairman of Align Technology, and also served as board chairman of Heartware, Inc. prior to its acquisition by Medtronic, plc. He received his B.S. degree in Industrial Management from LaSalle University and is a former captain in the United States Marine Corps.
Dr. Breckenridge was appointed as a director in January 2015. Dr. Breckenridge is currently working on the establishment of a new biotechnology company in Europe. He was formerly Chief Executive Officer, then Chief Medical Officer, of Silver Creek Pharmaceuticals, San Francisco, California. He obtained his medical degree from Oxford University, followed by his PhD in Developmental Biology at the University of Cambridge and completed his training in Clinical Pharmacology at University College London where he led the London Clinical Pharmacology rotation and chaired the UK Specialist Advisory Committee for Clinical Pharmacology and Therapeutics. Dr. Breckenridge is an academic board member of Empower India, and the Cornelia de Lange Society of Great Britain. He is a Fellow of the Royal College of Physicians of London.
Mr. Dovey has served as a director since June 2001, and was elected Chairman of the Board in March 2016. Since 1988, Mr. Dovey has been a partner of Domain Associates, LLC, a private venture capital management firm focused on life sciences, where he has led innovative investments and has established and directed new initiatives such as the collaboration between Domain and RUSNANO. Since joining Domain, he has served on the board of directors of over 35 private and public companies and has been Chairman of five. He currently sits on the board of two public companies: REVA, and Orexigen Therapeutics. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now part of Sanofi‑Aventis), a pharmaceutical and medical device company listed on the NYSE. As president of Rorer from 1986 to 1988, he was the primary architect of the company’s strategic shift to pharmaceuticals. Previous to that, he was President of Survival Technology, Inc., a start‑up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation, and New York Telephone. Mr. Dovey has served as both President and Chairman of the National Venture Capital Association. He is former Chair and currently serves on the Board of Trustees of the Wistar Institute, a non‑profit preclinical biomedical research company. Mr. Dovey serves on the board of directors and is also Chairman at the Center for Venture Education (Kauffman Fellows Program) and on the La Jolla Playhouse Board of Trustees. He was also a former board member of the industry association representing the medical device industry, as well as the association representing consumer pharmaceuticals. He is a trustee emeritus of Germantown Academy and is a former trustee of the University of Pennsylvania School of Nursing and the Burnham Institute for Medical Research. Mr. Dovey received his B.A. in mathematics from Colgate University and his MBA from the Harvard Business School.
Mr. Stockman, our co founder, has been a director since 1999, and was our Chairman of the Board from1999 to March 2016. He also served as our Chief Executive Officer from August 2010 to September 18, 2015. He served as a director of HeartWare Limited/HeartWare International, Inc., a NASDAQ-listed medical device company, between December 2006 and July 2016, when the company was acquired by Medtronic. He previously served on the boards of ZELTIQ Aesthetics, Inc., a medical technology company listed on NASDAQ, from July 2010 until April 2012 and MuseAmi, Inc, a privately held advanced music software company that he co-founded. Since 1999, Mr. Stockman has been the President and Chief Executive Officer of Group Outcome LLC, a U.S.-based merchant banking firm that deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies. Mr. Stockman also co-founded Centrimed, Inc., an internet-based software company, that was acquired by the Global Healthcare Exchange, LLC, and led the buyouts of Ioptex, an intraocular lens manufacturer, and two Johnson & Johnson divestitures, “A” Company Orthodontics, Inc. and Critikon Company, LLC, each of which was subsequently acquired. Prior to establishing Group Outcome LLC, Mr. Stockman spent 18 years with Johnston Associates, Inc. and Narragansett Capital Corporation, where he focused on venture capital investments and merger advisory work in health care. Mr. Stockman holds a Bachelor’s Degree from Harvard College and an MBA from The Tuck School at Dartmouth College, where he serves on Tuck’s Board of Overseers.
Mr. Thomas has served as a director since July 2010. He has also served as a director and non‑executive Chairman of the Board of HeartWare Limited/HeartWare International, Inc., a NASDAQ-listed medical device company, since November 2004. He is currently a director of a number of Australian public companies, including Virgin Australia Limited and Biotron Limited; he is Chairman of Starpharma Limited. Between October 2004 and September 2008, Mr. Thomas was a consultant to Citigroup Corporate and Investment Bank. Between March 2003 and September 2004, he was Chairman of Global Corporate and Investment Bank, Citigroup Global Markets, Australia and New Zealand. Prior to that time, Mr. Thomas was Chief Executive Officer of Citigroup’s Corporate and Investment Bank (formerly known as Salomon Smith Barney), Australia and New Zealand from October 1999 until February 2003. Mr. Thomas is Chairman of Aus Bio Limited, a director of O’Connell Street Associates and Chairman of Grahger Capital Securities. He also is a member of the advisory board of Inteq Limited. Mr. Thomas holds a Bachelor of Economics from Monash University, Australia. He is a member of the Stockbrokers Association of Australia and is a Master Stockbroker. Mr. Thomas is also a Fellow of the Financial Services Institute of Australia and the Australian Institute of Company Directors. He is on the board of the NSW State Library Foundation and serves on NSW State Library’s Audit and Risk Committee.